BRCA2 and breast cancer: The authors concluded (assumedly based on their case‐control findings alone) that carriers of the BRCA2 c.68‐7T > A variant have increased risk for breast cancer in families selected due to aggregation of breast cancer, and state in their discussion “...carriers of the variant should be informed that they probably have a clinically actionable pathogenic variant and referred to health care accordingly”.